Member Info for redboy33

Good Morning,
I asked question this morning from Walbrook regards following and sharing the response:

Q. "Can you advise the length/term of the government manufacturing contract or is it open ended?"
A. "I don’t know the answer to your first question so I’m just checking (a) what that is, and (b) whether Omega are precluded from disclosing this – details of the contract and that aspect of the announcement were subject to DHSC scrutiny so I’m not sure what else can be confirmed if not in the statement. I’ll have to come back to you on that."

Q. "Presumably the TT is still ongoing as well?"
A. "Mologic tech transfer is still continuing."

Will post any further updates if I receive.

ATB Red

Hi Flashy,
There is a 15 minute time delay. If you check again at 16:46 the correct price should be shown.
ATB
Red

Good Evening,
There was a post (Jack smith) on Twitter approx. 17:30 intimating a number of large Sells from yesterday (4th Feb.) but reported only after hours today. For those without access to full listing my investigation (and opinion) of these 'Sells' is as follows:
08:52 sell price 67.0p 60,000 £40,200 reported as sell and as trading range was 66-69 does appear to be a sell
09:40 sell price 68.90 72,554 £49,999 reported as sell, trading range 66-69 so suggest this was actually a Buy
10:15 sell price 67.25 50,515 £33,970 reported as sell and as trading range 66-69 a sell
10:32 sell price 68.42 43,832 £29,999 reported as sell, trading range 66-69 so suggest this was a Buy
14:47 sell price 69.02 36,750 £25,360 reported as sell, trading range 68-70 so suggest this was a Buy

Have a good weekend and hope next week we get some positive news!

ATB
Red

Completely agree Asher, news imminent!

Thanks BigDano, appreciate the response.

TW,
It is not clear though if in 4 months in order to get from 500k to 2m they will need to work 7 days and more importantly if as you say it is only 5 then why?

Good Morning,
I contacted Walbrook a week ago to try and clarify what the full production capacity was at Alva. I did this as over the last 2 weeks I believe there had been a couple of posts referencing 5 day working weeks. I had always assumed that they would want to ‘sweat the asset’ and build to a 24/7 model.
I received a response back yesterday which basically said that they thought this level of detail (of information) was not appropriate to divulge to investors. I challenged this response because in my original message I made it clear that if they are only planning to work a 5 day week and can get to 2m units a week (through utilising/adding more space, staff and machinery) that would suggest they can produce 400k units a day. More importantly, if they utilised the weekends then that would suggest the opportunity is there to produce a further 800k units (i.e. c2.8m/week).
My background is operations and running distribution centres and have always worked on the principle that it was my responsibility to ‘sweat the asset’ (as long as demand so warrants) and I know weekend working can be unpopular/have its challenges but I was quite taken aback by the Walbrook response. As an investor (and I believe quite a significant one) I believe I have every right to know whether one of the sites I am invested in is capable (in time) to increase its production by 40% because that would increase revenue, reduce CPU and increase the SP.
Perhaps I or, they have misunderstood what I am asking or possibly someone else knows the answer, or enjoys a better relationship than I do with Walbrook and can clarify whether in April 2021 the requirement is to work the Alva site 24/7 or 24/5?
ATB
Red

Good Mng Symbol,
I have been trying to buy this morning (c20k shares) and NT each time. Broke down to 8,640 trade that is showing but the 15,802 shares not showing at time of posting.
ATB
Red

Good Morning,
I thought I would just share an e mail I sent this morning to Walbrook and response. No real news unfortunately. I was hoping Finn Cap might produce an update in same format as per their 22nd June Company Note - Pg 10-11) to reflect increased capacity from April.

Question:
"Sorry to bother you but the challenge of attracting Institutional Investors is an area that I do not believe gets a great deal of discussion but one which (in my opinion) is key to the company achieving the potential the hard work of Colin and team deserves.

I appreciate that Finn Cap are adamant (ref. 30th November Company Note) that they cannot produce an indicative target SP but without this how do you ‘sell’ the potential to an institutional investor? I would have assumed that a key factor for them would be, “if I invest £1m in ODX what might that be worth in 3 years time?” A number of investors have attempted to forecast future SP using low and high assumptions around revenue and I don’t understand why Finn Cap cannot do the same (as long as they state the assumptions their figures are based on).

Perhaps I’m wrong in my assumptions above and Finn Cap are right but then it would be great to have some feedback on how they are attempting to attract Institutions to invest (without forecasted SP’s) and (ideally) any update as to their progress? About 2 weeks ago when the markets were much more active (strangely quiet last few days) I believe there were a number of significant buys and hoped a TR1 would land announcing a new II (and maybe still will) but nothing yet."

Answer:
"I’m going to be out of the office today – but I think the answer to your question is in the 22 June finnCap not which shows institutional investors the revenue and growth profit potential for manufacturing of both ELISA and Lateral Flow based on capacity usage. This is exactly what you would do when you can’t forecast with certainty what volumes will be but you can indicated to institutional investors what the potential can be – based on those metrics and the assumptions of risk of delivering capacity utilisation they can make their own conclusions on potential target valuations.

I’m afraid finnCap don’t provide updates on how they go about their job of liaising with institutional investors on behalf of their clients so I can’t help any further. I’m sure they had arrangements in place for the company to update institutional shareholders this week following their results announcement,."

ATB
Red

Good Afternoon Chuggley,
Your very welcome.
I take the comment from Walbrook, "Omega only had agreement from Mologic to announce what they did today and within their results statement not as a standalone announcement." very positively. Again, in my opinion, it sounds like ODX have wanted to confirm its all systems go on the Mologic Antigen Test and now its just a matter of when (we are producing and selling vast amounts) and not IF:-).
ATB
Red

Good Afternoon,
I contacted Walbrook this morning after JAdam posted that TT had commenced, specifically as I assumed this would warrant an RNS in its own right, the response I received is below:

" In the statement this morning the Company confirmed that has now established its technology transfer team and Colin confirms in his presentation that the process has commenced.
Omega only had agreement from Mologic to announce what they did today and within their results statement not as a standalone announcement."

So my understanding is that TT has commenced and soon (in my opinion) we will get an RNS.

ATB
Red

Completely agree JG.
JBER (MM) have been very active last 2 weeks and to best of my knowledge today is first day they have been almost inactive and FCAP same, so maybe a TR1 RNS inbound.
ATB
Red

Excellent post thank you. However, I would argue that silence is never good when things are not going well (SP fall over last few weeks). I appreciate that there may be little of material value (or new news) that can be announced but in my experience just to hear the business reaffirm all is good and we continue to welcome news of more vaccine treatments as that will provide excellent, additional opportunities, would perhaps at least calm and reassure.
Thanks
Red

MB, wish you would speak to Colin about taking over the company PR!

Good Afternoon Smishman,

I sent the (below) e mail yesterday to Walbrook as sick of poor comms.

If I may, the only other point I would add is that in my opinion Finn Cap should be/have produced a new Brokers Note to reflect the exciting growth and I would suggest they support it with a bar chart (like in Colin's presentation):
1) 1st Bar for 2021 and bar colour coded to reflect different product streams and revenue/profit value mainly I expect CV19.
2) 2nd Bar 2022 same principle and still would expect CV19 dominance but growing Food Detective share in China and maybe Food Print in USA
3) 3rd Bar 2023 start to show (perhaps) slowing down of CV19, growing Food tolerance products and possibly start of 2 new products they said they aimed to be developing.

E Mail below:
Thanks for your e mail.

As I type the SP is down 2.65% and half what it was only a few weeks ago. I feel the communications from Walbrook/ODX are far too few and too reactive/late. I am not going to write again after this message as frankly the responses I receive give me no confidence that Walbrook/ODX care whatsoever about their investors.

We have been impacted by two vaccine announcements and lacked the real punchy and enthusiastic communications embracing this news and using it to our advantage as well as (thereafter) continually ‘putting it out there’ that we welcome Astra Zeneca (and any others) as our tests will be required to test before and after. CIGA announcement looked great and tagged by Walbrook but not ODX. Indeed today it has been mentioned about the lack of activity on the ODX twitter.

I say again why do we hear so little from our Sales and Marketing Director, Jag when so much is on the horizon.

I take what you say about the possible legal case but cannot help but feel this is linked to the overdue MHRA approval, although even if that came now, frankly I’m not convinced it would boost the SP. This brings me back to a point I have raised several times before, Institutional Investors!:
1. Where are the ones that oversubscribed for the last (debacle) of a placing? Surely now at such great prices they should be increasing their holdings and TR1’s in the post. In reality they probably have reduced or even sold all their holdings a long time ago.
2. What has Finn Capp (I assume their primary responsibility) actually done to attract new II’s? the SP movement of the last few weeks underlines their importance. There is clearly far too many short term investors/traders proportionately.
3. Sneller has gone but are his shares still being sold by charities? Are L & G out or still selling? I know another investor raised the question why could Finn Cap not find a buyer for Sneller/L & G.

ATB
Red

I would not say that ODX are the exception in terms of being poor at communication but certainly one of the poorest (in my experience/opinion).
An example I would offer is that why wait for AZ to announce they have a vaccine why not communicate/promote the fact now (and keep doing it) that ODX welcomes any vaccines because their tests will be required and to underline the fact we are increasing our manufacturing capacity 10 fold.
And just while I am getting this off my chest is it only me that is surprised that we so rarely hear anything from our Global Sales and Marketing Director, Jag? I would have thought with all we have in the pipeline he would be on the ODX Twitter page at least every week?

First time i have laughed today! Thank you

Checking the price range this transaction 32,604 went through at 10:54 was 45 - 46 so this was actually a Buy

Interesting buy at 46.95 at 1020 (range 42 - 44 at that time) for 400k shares

Good Afternoon Matt,
I asked a similar question to Walbrook:
Question:
"The MHRA application is what I believe most investors are disappointed with as there are no actual reasons given for the time (are questions being asked on the data/under resourced etc.) but when (as per my e mail) top scientists state 3 weeks more to assess Pfizer data and then 2 weeks (beginning of December) to fast-track and add to that Han**** yesterday suggesting vaccines available in December it poses the question why and how a vaccine should have priority for a test already approved for professional use and presumably relatively straightforward compared to giving assurances of side effects to a vaccine?"
ANSWER:
"I think you’re asking me to comment on why a vaccine might be given priority over home-use of the UK RTC’s antibody test by the MHRA. Given that Abingdon are in dialogue with the MHRA on this approval process the Consortium have been very careful not to make any public statements or provide commentary on the process and so I can’t really answer that question."
Not very helpful I'm afraid.
Checking through the Q & A (at least to Q184) MHRA seems to be the no.1
ATB
Red